KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2025)

Aurinia Pharmaceuticals' EBT history spans 7 years, with the latest figure at $35.7 million for Q4 2025.

  • For Q4 2025, EBT rose 2942.63% year-over-year to $35.7 million; the TTM value through Dec 2025 reached $114.2 million, up 1432.72%, while the annual FY2025 figure was $114.2 million, 1432.72% up from the prior year.
  • EBT reached $35.7 million in Q4 2025 per AUPH's latest filing, up from $32.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $35.7 million in Q4 2025 to a low of -$50.4 million in Q1 2021.
  • Average EBT over 5 years is -$12.1 million, with a median of -$12.6 million recorded in 2023.
  • Peak YoY movement for EBT: crashed 92.48% in 2021, then skyrocketed 2942.63% in 2025.
  • A 5-year view of EBT shows it stood at -$32.6 million in 2021, then rose by 22.72% to -$25.2 million in 2022, then decreased by 4.86% to -$26.4 million in 2023, then skyrocketed by 104.44% to $1.2 million in 2024, then surged by 2942.63% to $35.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EBT are $35.7 million (Q4 2025), $32.0 million (Q3 2025), and $22.2 million (Q2 2025).